- 令和
- 北京
- スタッフ
- スタート
- 医学
- 医療
- 取得
- 新型肺炎
- 測定
- 臨床研究
「イムノグロブリン」の写真・グラフィックス・映像
- 提供元
- 日付
- 種類
- 向き
- カテゴリ
- 色
- 提供元
- 日付
- 24時間以内 0
- 48時間以内 0
- 72時間以内 0
- 7日以内 0
- 30日以内 0
- 1年以内 4
- 期間を指定 21
- 日付指定なし 21
- 種類
- 写真 21
- グラフィックス 0
- 映像 0
- 向き
- 縦 3
- 横 18
- 正方形 0
- カテゴリ
- ニュース
- スポーツ
- エンターテインメント
- 教育向け
- カテゴリ指定なし
- 色
- カラー 20
- モノクロ 1
- 古い順
- 1
- 古い順
1994年02月23日「ガンマガード」 輸入免疫製剤を自主回収米国バクスター社の免疫グロブリン製剤「ガンマガード」（薬品）
商品コード: 1994022300087
2020年03月16日中国、新型コロナ不活化ワクチン開発で進展臨床試験開始へ北京科興中維生物技術の品質検査室で、新型コロナウイルス不活化ワクチンの免疫グロブリンＧ抗体価を測定するスタッフ。（３月１６日撮影）中国国務院合同予防抑制メカニズムの科学研究難関攻略グループは１４日、中国の２種類の新型コロナウイルス不活化ワクチンが国家薬品監督管理局から第１相と第２相の統合臨床試験の許可を得たことを明らかにした。関連の臨床試験が同時にスタートする。これは臨床研究の許可文書を取得した初の新型コロナウイルス不活化ワクチンとなる。（北京＝新華社記者／張玉薇）＝２０２０（令和２）年３月１６日、クレジット：新華社／共同通信イメージズ
商品コード: 2020041501220
2021年09月03日China Covid-19 MedicineA view of two doses of Human Immunoglobulin (pH4) for Intravenous injection (COVID-19) made by Sinopharm exhibited at the China International Fair for Trade in Services (CIFTIS) in Beijing, China Friday, Sept. 03, 2021. The IgG antibodies extracted from recovered patients of COVID- 19 are expected to boost the immune response in newly infected patients.、クレジット：Ｆｅａｔｕｒｅｃｈｉｎａ／共同通信イメージズ ※中国での使用禁止。
商品コード: 2021090410061
2021年09月03日China Covid-19 MedicineA view of two doses of Human Immunoglobulin (pH4) for Intravenous injection (COVID-19) made by Sinopharm exhibited at the China International Fair for Trade in Services (CIFTIS) in Beijing, China Friday, Sept. 03, 2021. The IgG antibodies extracted from recovered patients of COVID- 19 are expected to boost the immune response in newly infected patients.、クレジット：Ｆｅａｔｕｒｅｃｈｉｎａ／共同通信イメージズ ※中国での使用禁止。
商品コード: 2021090410040
2021年09月03日China Covid-19 MedicineA view of two doses of Human Immunoglobulin (pH4) for Intravenous injection (COVID-19) made by Sinopharm exhibited at the China International Fair for Trade in Services (CIFTIS) in Beijing, China Friday, Sept. 03, 2021. The IgG antibodies extracted from recovered patients of COVID- 19 are expected to boost the immune response in newly infected patients.、クレジット：Ｆｅａｔｕｒｅｃｈｉｎａ／共同通信イメージズ ※中国での使用禁止。
商品コード: 2021090410089
2021年09月03日China International Trade Fair in Services 2021Photo taken on September 3, 2021 shows the intravenous injection human immunoglobulin (pH4) developed by Sinopharm China Bio at the China International Trade Fair in Services 2021 in Beijing, China.＝２０２１（令和３）年９月３日、クレジット：ＣＦＯＴＯ／共同通信イメージズ
商品コード: 2021092104914
2021年09月03日China International Trade Fair in Services 2021Photo taken on September 3, 2021 shows the intravenous injection human immunoglobulin (pH4) developed by Sinopharm China Bio at the China International Trade Fair in Services 2021 in Beijing, China.＝２０２１（令和３）年９月３日、クレジット：ＣＦＯＴＯ／共同通信イメージズ
商品コード: 2021092104888
2021年09月03日Intravenous immunoglobulin vials at the 2021 China International Fair for Trade in Services in China - 03 Sept 2021September 3, 2021, Beijing, China: Intravenous COVID-19 human immunoglobulin (pH4) vials seen displayed at the 2021 China International Fair for Trade in Services (CIFTIS)..On August 30, the intravenous COVID-19 human immunoglobulin (pH4) developed by Sinopharm was given clinical trial approval issued by the National Medical Products Administration (NMPA). It is reported that this product is unique in the world, and there is no other manufacturer in the world carrying out clinical application of intravenous COVID-19 human immunoglobulin based on plasma after immunization with the COVID-19 vaccine that is already on the market. (Credit Image: © Sheldon Cooper/SOPA Images via ZUMA Press Wire)、クレジット：©Ｓｈｅｌｄｏｎ Ｃｏｏｐｅｒ／ＳＯＰＡ Ｉｍａｇｅｓ ｖｉａ ＺＵＭＡ Ｐｒｅｓｓ Ｗｉｒｅ／共同通信イメージズ
商品コード: 2021090603863
2021年09月03日China International Trade Fair in Services 2021Photo taken on September 3, 2021 shows the intravenous injection human immunoglobulin (pH4) developed by Sinopharm China Bio at the China International Trade Fair in Services 2021 in Beijing, China.＝２０２１（令和３）年９月３日、クレジット：ＣＦＯＴＯ／共同通信イメージズ
商品コード: 2021092104850
2021年09月03日China International Trade Fair in Services 2021Photo taken on September 3, 2021 shows the intravenous injection human immunoglobulin (pH4) developed by Sinopharm China Bio at the China International Trade Fair in Services 2021 in Beijing, China.＝２０２１（令和３）年９月３日、クレジット：ＣＦＯＴＯ／共同通信イメージズ
商品コード: 2021092104754
2021年09月03日China International Trade Fair in Services 2021Photo taken on September 3, 2021 shows the intravenous injection human immunoglobulin (pH4) developed by Sinopharm China Bio at the China International Trade Fair in Services 2021 in Beijing, China.＝２０２１（令和３）年９月３日、クレジット：ＣＦＯＴＯ／共同通信イメージズ
商品コード: 2021092104642
2021年09月06日Intravenous Human Immunoglobulin For COVID-19 (pH4)An intravenous injection human immunoglobulin for COVID-19 (pH4) developed by Sinopharm China Bio is displayed at the China (Beijing) International Trade Fair in Services 2021, September 6, 2021, Beijing, China.＝２０２１（令和３）年９月６日、クレジット：ＣＦＯＴＯ／共同通信イメージズ
商品コード: 2021091002049
2021年09月06日Intravenous Human Immunoglobulin For COVID-19 (pH4)An intravenous injection human immunoglobulin for COVID-19 (pH4) developed by Sinopharm China Bio is displayed at the China (Beijing) International Trade Fair in Services 2021, September 6, 2021, Beijing, China.＝２０２１（令和３）年９月６日、クレジット：ＣＦＯＴＯ／共同通信イメージズ
商品コード: 2021091001972
2021年09月06日Intravenous Human Immunoglobulin For COVID-19 (pH4)An intravenous injection human immunoglobulin for COVID-19 (pH4) developed by Sinopharm China Bio is displayed at the China (Beijing) International Trade Fair in Services 2021, September 6, 2021, Beijing, China.＝２０２１（令和３）年９月６日、クレジット：ＣＦＯＴＯ／共同通信イメージズ
商品コード: 2021091001885
2021年09月06日Intravenous Human Immunoglobulin For COVID-19 (pH4)An intravenous injection human immunoglobulin for COVID-19 (pH4) developed by Sinopharm China Bio is displayed at the China (Beijing) International Trade Fair in Services 2021, September 6, 2021, Beijing, China.＝２０２１（令和３）年９月６日、クレジット：ＣＦＯＴＯ／共同通信イメージズ
商品コード: 2021091002174
2021年09月06日Intravenous Human Immunoglobulin For COVID-19 (pH4)An intravenous injection human immunoglobulin for COVID-19 (pH4) developed by Sinopharm China Bio is displayed at the China (Beijing) International Trade Fair in Services 2021, September 6, 2021, Beijing, China.＝２０２１（令和３）年９月６日、クレジット：ＣＦＯＴＯ／共同通信イメージズ
商品コード: 2021091002328
2021年09月06日Intravenous Human Immunoglobulin For COVID-19 (pH4)An intravenous injection human immunoglobulin for COVID-19 (pH4) developed by Sinopharm China Bio is displayed at the China (Beijing) International Trade Fair in Services 2021, September 6, 2021, Beijing, China.＝２０２１（令和３）年９月６日、クレジット：ＣＦＯＴＯ／共同通信イメージズ
商品コード: 2021091002176
2022年09月21日Autoimmune DisorderSeptember 21, 2022, DUBUQUE, IOWA, USA: Carole Schmidt, left undergoes Intravenous immunoglobulin (IVIg) therapy for Immune thrombocytopenia (also known as ITP) at the MercyOne Cancer Center in Dubuque, Iowa. ITP is an autoimmune disorder causing internal bruising and an increased incidence of sometimes life-threatening internal bleeding. Bleeding occurs because the immune system attacks a certain type of cell - platelets - which are needed to help control bleeding. ITP is more common among young women and children. The risk appears to be higher in people who also have diseases such as rheumatoid arthritis, lupus and antiphospholipid syndrome. Research indicates ITP patients often have had a virus or viral infection about three weeks before developing ITP. Scientists believe that the body, when making antibodies against the virus, may have ‘‘accidentally‘‘ made an antibody that sticks to the platelet cells. The body then recognizes these platelet cells with antibodies as foreign cells and destroys them. Th...
商品コード: 2022092703185
2022年09月21日Autoimmune DisorderSeptember 21, 2022, DUBUQUE, IOWA, USA: Immune Globulin Intravenous is used in intravenous immunoglobulin therapy (IVIg) to raise blood platelet counts quickly. IVIg is an infusion given with a needle and requires sitting still for some time in an infusion center while the medicine goes into the veins. Most patients with Immune thrombocytopenia (ITP) start with a round of steroids to stop the body from destroying platelets and quickly raise platelet counts. Unfortunately, steroids can also have side effects, such as insomnia, weight gain, and mood changes. Thatââ¬â¢s 1 of the reasons why the American Society of Hematology (ASH) recommends the use of steroids for no more than 6 weeks. (Credit Image: © Kevin E. Schmidt/ZUMA Press Wire)、クレジット：©Ｋｅｖｉｎ Ｅ． Ｓｃｈｍｉｄｔ／ＺＵＭＡ Ｐｒｅｓｓ Ｗｉｒｅ／共同通信イメージズ
商品コード: 2022092703152
2022年09月21日Autoimmune DisorderSeptember 21, 2022, DUBUQUE, IOWA, USA: Immune Globulin Intravenous is used in intravenous immunoglobulin therapy (IVIg) to raise blood platelet counts quickly. IVIg is an infusion given with a needle and requires sitting still for some time in an infusion center while the medicine goes into the veins. Most patients with Immune thrombocytopenia (ITP) start with a round of steroids to stop the body from destroying platelets and quickly raise platelet counts. Unfortunately, steroids can also have side effects, such as insomnia, weight gain, and mood changes. Thatââ¬â¢s 1 of the reasons why the American Society of Hematology (ASH) recommends the use of steroids for no more than 6 weeks. (Credit Image: © Kevin E. Schmidt/ZUMA Press Wire)、クレジット：©Ｋｅｖｉｎ Ｅ． Ｓｃｈｍｉｄｔ／ＺＵＭＡ Ｐｒｅｓｓ Ｗｉｒｅ／共同通信イメージズ
商品コード: 2022092703165
2022年09月21日Autoimmune DisorderSeptember 21, 2022, DUBUQUE, IOWA, USA: Immune Globulin Intravenous is used in intravenous immunoglobulin therapy (IVIg) to raise blood platelet counts quickly. IVIg is an infusion given with a needle and requires sitting still for some time in an infusion center while the medicine goes into the veins. Most patients with Immune thrombocytopenia (ITP) start with a round of steroids to stop the body from destroying platelets and quickly raise platelet counts. Unfortunately, steroids can also have side effects, such as insomnia, weight gain, and mood changes. Thatââ¬â¢s 1 of the reasons why the American Society of Hematology (ASH) recommends the use of steroids for no more than 6 weeks. (Credit Image: © Kevin E. Schmidt/ZUMA Press Wire)、クレジット：©Ｋｅｖｉｎ Ｅ． Ｓｃｈｍｉｄｔ／ＺＵＭＡ Ｐｒｅｓｓ Ｗｉｒｅ／共同通信イメージズ
商品コード: 2022092703213
- 1
